Xeris Biopharma Holdings Inc (STU:2B30)
€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q4 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript

Mar 10, 2022 / 01:30PM GMT
Release Date Price: €2.3 (+5.50%)
Operator

Hello, everyone, and welcome to the Xeris Biopharma Fourth Quarter 2021 Financial Results Conference Call and Webcast. My name is Seb, and I'll be the operator for your call today. (Operator Instructions)

I will now hand the floor over to Allison Wey to begin. Please go ahead.

Allison Wey
Xeris Biopharma Holdings, Inc. - SVP of IR & Corporate Communications

Thank you. Good morning, and welcome to Xeris Biopharma's Fourth Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast. A press release of the company's fourth quarter and full year 2021 financial results was issued earlier this morning and can be found on our website.

We are also joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. Paul will provide opening remarks and Steve will provide details on our financial results, and then we will open the call for Q&A.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris' business practices, Xeris' future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot